Shares of CymaBay Therapeutics Inc (NASDAQ:CBAY) reached a new 52-week high during mid-day trading on Monday . The stock traded as high as $14.98 and last traded at $14.98, with a volume of 1400500 shares changing hands. The stock had previously closed at $14.87.
CBAY has been the topic of several recent research reports. Piper Jaffray Companies reissued a “buy” rating and issued a $12.00 price target on shares of CymaBay Therapeutics in a research note on Friday, October 27th. Oppenheimer set a $15.00 price target on CymaBay Therapeutics and gave the company a “buy” rating in a research note on Wednesday, January 10th. HC Wainwright reissued a “buy” rating and issued a $12.00 price target on shares of CymaBay Therapeutics in a research note on Tuesday, November 28th. Zacks Investment Research downgraded CymaBay Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, January 16th. Finally, BidaskClub raised CymaBay Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, January 26th. Two investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $16.56.
The company has a debt-to-equity ratio of 0.04, a quick ratio of 7.39 and a current ratio of 7.39. The company has a market capitalization of $657.08, a PE ratio of -14.83 and a beta of 2.04.
In related news, Director Kurt Von Emster sold 218,057 shares of CymaBay Therapeutics stock in a transaction dated Wednesday, February 14th. The stock was sold at an average price of $15.89, for a total value of $3,464,925.73. The transaction was disclosed in a filing with the SEC, which is available at this link. In the last ninety days, insiders sold 964,787 shares of company stock worth $11,554,836. 15.10% of the stock is owned by company insiders.
A number of institutional investors have recently bought and sold shares of CBAY. Bank of New York Mellon Corp grew its holdings in CymaBay Therapeutics by 0.8% during the second quarter. Bank of New York Mellon Corp now owns 17,344 shares of the biopharmaceutical company’s stock worth $100,000 after purchasing an additional 140 shares during the period. Vanguard Group Inc. grew its holdings in CymaBay Therapeutics by 20.7% during the second quarter. Vanguard Group Inc. now owns 991,633 shares of the biopharmaceutical company’s stock worth $5,712,000 after purchasing an additional 170,126 shares during the period. Omega Fund Management LLC grew its holdings in CymaBay Therapeutics by 82.9% during the third quarter. Omega Fund Management LLC now owns 551,477 shares of the biopharmaceutical company’s stock worth $4,445,000 after purchasing an additional 250,000 shares during the period. Ameriprise Financial Inc. bought a new position in CymaBay Therapeutics during the third quarter worth about $1,536,000. Finally, EAM Investors LLC bought a new position in CymaBay Therapeutics during the third quarter worth about $4,788,000. Institutional investors and hedge funds own 60.12% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This news story was first reported by Stock Observer and is owned by of Stock Observer. If you are reading this news story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://www.thestockobserver.com/2018/02/21/cymabay-therapeutics-cbay-sets-new-52-week-high-at-14-98.html.
CymaBay Therapeutics Company Profile
CymaBay Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout.
Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.